- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Nivolumab, Bevacizumab, Pemetrexed, Best Supportive Care, nab-Paclitaxel, Paclitaxel, Docetaxel, Gemcitabine, Erlotinib, Crizotinib, Carboplatin
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 341 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 133
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 117 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 1,102
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bladder Cancer
- Interventions
- Pembrolizumab, Enfortumab vedotin (EV), RC + PLND, Gemcitabine, Cisplatin
- Biological · Procedure · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 808 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Fullerton, California • Los Angeles, California + 19 more
- Conditions
- Chronic Myocardial Ischemia, Refractory Angina Pectoris, Advanced Coronary Heart Disease
- Interventions
- Auto-CD34+ cells, Placebo: Diluent used to suspend Auto-CD34+ cells, Standard of care
- Biological · Other
- Lead sponsor
- Lisata Therapeutics, Inc.
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 38 more
- Conditions
- Diabetic Foot Ulcer
- Interventions
- Standard of Care, Nitric Oxide Therapy 2x week 6 min. plus standard of care, Nitric Oxide Therapy 2x week 12 min. plus standard of care, Nitric Oxide Therapy 4x week 6 min. plus standard of care, Nitric Oxide Therapy 4x week 12 min. plus standard of care
- Device
- Lead sponsor
- Origin Inc.
- Industry
- Eligibility
- 22 Years to 85 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 15
- States / cities
- Montgomery, Alabama • Phoenix, Arizona • Tucson, Arizona + 11 more
- Conditions
- Neoplasms
- Interventions
- GSK5764227, Bevacizumab, Fluorouracil, leucovorin, Enzalutamide
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 5
- States / cities
- Reunion, Florida • New Hyde Park, New York • Philadelphia, Pennsylvania + 2 more
- Conditions
- Suspected or Known Squamous Cell Neoplasia, Prior History of Squamous Cell Dysplasia and /or Neoplasia
- Interventions
- Proflavine Hemisulfate, Artificial Intelligence Mobile High-Resolution Microendoscope
- Drug · Device
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Asthma
- Interventions
- GSK3511294, Placebo
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 397 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 41
- States / cities
- Alabaster, Alabama • Mobile, Alabama • Phoenix, Arizona + 34 more
- Conditions
- Dilated Cardiomyopathy
- Interventions
- Ixmyelocel-T, Standard of Care
- Biological · Other
- Lead sponsor
- Vericel Corporation
- Industry
- Eligibility
- 18 Years to 86 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Cleveland, Ohio • Dallas, Texas + 2 more
- Conditions
- Multiple Sclerosis
- Interventions
- SARS-COV-2 mRNA Vaccine
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Denver, Colorado • New York, New York
- Conditions
- Unresectable Metastatic Colorectal Cancer
- Interventions
- ABBV-400, Bevacizumab, Folinic Acid, Fluorouracil, Irinotecan
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Duarte, California + 15 more
- Conditions
- Human Immunodeficiency Virus, Smoking Cessation, Smoking, Cigarette, Smoking, Anxiety, Depression, Nicotine Dependence
- Interventions
- QUIT, Time-Matched Control (TM)
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Houston, Texas
- Conditions
- NSCLC
- Interventions
- EIK1001, Pembrolizumab, Paclitaxel, Pemetrexed, Carboplatin
- Drug
- Lead sponsor
- Eikon Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 38
- States / cities
- Daphne, Alabama • Chandler, Arizona • Fresno, California + 33 more
- Conditions
- Acute Lymphoblastic Leukemia in Remission, Hodgkin Lymphoma in Remission, Non-Hodgkin Lymphoma in Remission, Cancer Survivorship
- Interventions
- Phentermine/Topiramate ER, Health Behavior and Lifestyle Counseling
- Drug · Behavioral
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 12 Years to 24 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- ARDS, Human, Lung, Wet, Thyroid, Pulmonary Edema, Lung Inflammation
- Interventions
- Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation., Non-intervention
- Drug · Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 2
- States / cities
- Edina, Minnesota • Minneapolis, Minnesota
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Selinexor, Pembrolizumab, Trifluridine, Tipiracil
- Drug
- Lead sponsor
- Karyopharm Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Newark, Delaware • Plantation, Florida
- Conditions
- Antithrombin III Deficiency, Covid19
- Interventions
- Antithrombin III
- Drug
- Lead sponsor
- Enrique Ginzburg
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Eyelid Squamous Cell Carcinoma, Recurrent Eyelid Squamous Cell Carcinoma, Recurrent Skin Acantholytic Squamous Cell Carcinoma, Recurrent Skin Clear Cell Squamous Cell Carcinoma, Recurrent Skin Lymphoepithelial Carcinoma, Recurrent Skin Spindle Cell Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Resectable Eyelid Squamous Cell Carcinoma, Resectable Skin Acantholytic Squamous Cell Carcinoma, Resectable Skin Clear Cell Squamous Cell Carcinoma, Resectable Skin Lymphoepithelial Carcinoma, Resectable Skin Spindle Cell Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Skin Acantholytic Squamous Cell Carcinoma, Skin Clear Cell Squamous Cell Carcinoma, Skin Lymphoepithelial Carcinoma, Skin Spindle Cell Squamous Cell Carcinoma, Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
- Interventions
- Biospecimen Collection, Cemiplimab, Computed Tomography, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Surgical Procedure
- Procedure · Biological · Radiation + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 196
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 147 more
- Conditions
- Pain, Postoperative, Opioid Use, Lumbar Spine Injury
- Interventions
- Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN), Sham Control Device
- Device
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Actinic Keratoses
- Interventions
- 5% 5-fluorouracil (5-FU) powder, 5% 5-fluorouracil (5-FU) powder PLUS 15% Aluminum Chloride Hexahydrate (ACH)
- Drug
- Lead sponsor
- West Virginia University
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Adenocarcinoma Esophagus, Locally Advanced Adenocarcinoma, Siewert Type I Adenocarcinoma of Esophagogastric Junction, Siewert Type II Adenocarcinoma of Esophagogastric Junction
- Interventions
- Vactosertib, Standard of Care Preoperative Therapy
- Drug
- Lead sponsor
- Melissa Lumish
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Hepatitis C, Chronic
- Interventions
- Copegus, Pegasys, RO4588161
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 516 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • La Jolla, California • Long Beach, California + 26 more
- Conditions
- Alveolar Bone Loss
- Interventions
- INFUSE® Bone Graft
- Device
- Lead sponsor
- Medtronic Spinal and Biologics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 6
- States / cities
- Loma Linda, California • Los Angeles, California • Sarasota, Florida + 3 more
- Conditions
- Glioma
- Interventions
- RS-fMRI
- Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2033
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- HIV Prevention Program, Pre-Exposure Prophylaxis (PrEP)
- Interventions
- Nurse-Led Intervention, Patient Navigation Intervention, Standard-of-care (SoC)
- Behavioral
- Lead sponsor
- Rhode Island Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island